The Atlanta Braves indeed face critical decisions regarding their starting pitching rotation this offseason. With Spencer Strider recovering from Tommy John surgery and uncertainty surrounding Max Fried and Charlie Morton, the team’s rotation depth is in flux. While Max Fried’s potential departure looms large, MLB.com’s Mark Feinsand suggests that Morton could return, citing his readiness to continue pitching and the Braves’ need for stability.
Morton, despite being 41, remains a solid contributor, with a respectable 4.19 ERA over 165.1 innings in 2024. His career ERA of 4.09 in Atlanta further underscores his consistency. Spotrac projects a one-year, $17 million deal for Morton, a reasonable price for a dependable veteran in a rotation that will also feature Chris Sale, Reynaldo López, Spencer Schwellenbach, and newly acquired Griffin Canning.
The Braves’ aggressive pursuit of Fried will be pivotal, but their approach to Morton could stabilize the rotation while Strider recovers. Balancing financial and performance priorities will define this offseason for Atlanta.
Leave a Reply